Patents by Inventor Sebastian Van Der Woning

Sebastian Van Der Woning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240026010
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: June 7, 2023
    Publication date: January 25, 2024
    Inventors: Jean-Michel PERCIER, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Patent number: 11713354
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 1, 2023
    Assignees: ARGENX BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Publication number: 20230088269
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 23, 2023
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • Patent number: 11447544
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: September 20, 2022
    Assignee: argenx BV
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • Patent number: 11261246
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: March 1, 2022
    Assignee: argenx BV
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • Patent number: 11230603
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Publication number: 20210332140
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: March 8, 2021
    Publication date: October 28, 2021
    Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
  • Publication number: 20210324061
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: November 12, 2020
    Publication date: October 21, 2021
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Patent number: 10875914
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: December 29, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stëphanie Liénart, Sophie Lucas, Pierre Coulie
  • Patent number: 10793627
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: October 6, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Publication number: 20200216528
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: October 23, 2019
    Publication date: July 9, 2020
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • Patent number: 10696741
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: June 30, 2020
    Assignee: argenx BVBA
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • Publication number: 20200181276
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Publication number: 20200157207
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: October 23, 2019
    Publication date: May 21, 2020
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • Patent number: 10604579
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: March 31, 2020
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Publication number: 20200095311
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Publication number: 20190375832
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: May 10, 2019
    Publication date: December 12, 2019
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Publication number: 20190367619
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: April 12, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
  • Patent number: 10479829
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 19, 2019
    Assignees: argenx BVBA, Université Catholique de Louvian
    Inventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie